Vor Bio (Nasdaq: VOR) has entered into an exclusive global license agreement with RemeGen for telitacicept, a novel dual-target fusion protein targeting autoimmune diseases. The deal grants Vor Bio rights outside Greater China for the late-stage asset, which is already approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).
Under the agreement, RemeGen will receive an initial payment of $125 million ($45 million upfront plus $80 million in warrants), potential regulatory and commercial milestones exceeding $4 billion, and tiered royalties. A global Phase 3 trial is currently enrolling patients with results expected in H1 2027.
Additionally, Vor Bio appointed Jean-Paul Kress, MD, as CEO and Chairman, replacing Robert Ang. Dr. Kress brings significant experience from leadership roles at MorphoSys, Syntimmune, and other biopharma companies
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.